The next catalyst for Abiomed following earnings last week is the release of the STEMI feasibility study on Impella in severe heart attack patients at the American Heart Association meeting in Chicago on November 11, Piper Jaffray analyst Matt O'Brien tells investors in a research note. The analyst anticipates the results of the feasibility study will prove positive and his analysis yields 200,000 U.S. STEMI patients and ~$5B market opportunity. A positive update on November 11 will likely push Abiomed shares even higher, O'Brien writes. He reiterates an Overweight rating on the shares with a $480 price target.